TX-MAVENIR
11.7.2022 15:02:06 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced multiple Communications Service Providers (CSPs) are upgrading their Business Support System (BSS) with Mavenir’s Digital Enablement Platform (MDE) to offer new digital services that monetize 5G network investments.
MDE is a cloud-native, catalog-driven digital BSS that enables CSPs to easily create new 5G digital offerings or complete the 5G network transformation with charging and mediation functions and can also be used to design a digital marketplace experience, bundling cross-industry partner products and services into unified offerings. “With Mavenir’s MDE platform, CSPs can innovate fearlessly by rapidly introducing new services, and capture their customers’ interest, to become an integral part of their digital life,” said Sandeep Singh, GM Digital Enablement at Mavenir.
MDE can run as a comprehensive BSS or importantly, as a digital overlay with existing legacy BSS for minimal risk and disruption. BSS digital overlay systems can help CSPs to maximize returns in the 5G era. Analysys Mason forecasts, “The digital overlay approach can also reduce costs considerably, potentially saving CSPs up to 50% over 3-5 years when compared with traditional transformation approaches.1 ”
Recent deployment examples of Mavenir’s MDE include:
- A leading CSP in Japan for business-to-business (B2B) mobility services
CSP successfully launched its Mobility Bundle Services targeted toward business customers. The typical service includes a bundle of SIM+Handsets purchased in bulk (10s-1000s). The BSS provided a first-of-its-kind agile, co-development, automated CI/CD enabling quarterly updates including modules like Product Catalog, CRM, CPQ, Order Management, Provisioning, Inventory tracking, Offline Rating & Charging, Billing, Invoicing, Payments and Collections.
Mavenir’s digital BSS, deployed as overlay BSS, is the primary for managing B2B customer account lifecycle and connects back to the existing consumer BSS, to leverage capabilities for Individual SIM activation, Number Portability workflow, Resource Inventory management and Network Mediation.
Deployment is on CSP's private cloud over the Kubernetes-based Containers-as-a-Service (CaaS) and Platform as a service (PaaS) layer.
- Large MVNO in Germany transitioning to MNO deploying MDE converged charging system (CCS) & Charging Gateway Function (CGF) for 4G+5G Converged Charging
Transitioning to becoming an MNO with owned RAN, Core, IT, BSS, and Charging system. The CCS includes the 4G OCS enabling Voice, SMS, Data service rating, and charging on real-time Diameter interfaces by integrating with the EPC and IMS network elements. The same core CCS engine also includes 5G CHF, integrated with Mavenir 5GC (5G Core) NFs. The Charging Gateway Function (CGF), also part of the CCS solution, provides for a modern microservice-based network and billing mediation functionality. While the first set of services, including 5G FWA is expected to go live in 2022, the solution is designed to deliver charging for Voice, Messaging, Data (4G+5G eMBB) and IoT in truly agile CI/CD based updates over the next two years. Deployment is on CSP's private cloud over the Kubernetes-based CaaS and PaaS layer.
- Greenfield CSP in Guyana selects MDE for E2E BSS and Charging
Deploying end-to-end BSS and Charging for their 4G+5G Mobile and Fixed Wireless service rollout. The first phase of this multi-phase enables the CSP to launch Prepaid LTE Voice, Data, and SMS services in 2022, leveraging a 4G OCS (Online Charging System) solution for prepaid voice, data, and messaging charging. The second phase will introduce Postpaid services built on top of the BSS. The final phase includes the launch of the 5G eMBB service that will be deployed using MDE 5G CCS integrated with the other vendor's 5GC.
Supporting material:
Mavenir Digital Enablement (MDE) Solution Brief
MDE Introduction Video
MDE Composable BSS Video
Mavenir’s Charging Gateway Function Solution Brief
Mavenir’s Converged Charging Solution Brief
Mavenir’s Converge Charging System Video
Other MDE resources –
MDE Digital Marketplace Whitepaper
MDE solution For MVNOs & Digital Brands
MDE IoT Business Management Solution Brief
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
1 Analysys Mason/Mavenir White Paper “BSS digital overlay systems can help CSPs to maximize returns in the 5G era ” – June 2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005119/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom